Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Medtronic MDT recently announced a patent litigation win related to its sacral neuromodulation device and termed it as ‘an important victory’. Specifically, the company’s sacral neuromodulation device ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...

Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...

Axonics AXNX recently announced that a jury in the U.S. District Court for the Central District of California ruled unanimously in its favor in a patent infringement lawsuit filed by Medtronic MDT.

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of ...